A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy(†)

Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for recurrent MG was progression-free survival at 6 months (PFS-6) and overall survival at 12 m...

Full description

Saved in:
Bibliographic Details
Main Authors: Raizer, Jeffrey J., Abrey, Lauren E., Lassman, Andrew B., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Yung, W.K. Alfred, Gilbert, Mark R., Aldape, Kenneth A., Wen, Patrick Y., Fine, Howard A., Mehta, Minesh, DeAngelis, Lisa M., Lieberman, Frank, Cloughesy, Timothy F., Robins, H. Ian, Dancey, Janet, Prados, Michael D.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2010
Subjects:
Clinical Investigations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940554/
https://ncbi.nlm.nih.gov/pubmed/20150372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop015
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items